Physician profile
Alan H Kramer
NPI 1144216656
$834.13
in general payments reported to CMS, 2019-2025
16 companies · $27.51 in 2025
The $27.51 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $91.72 · 2021: $363 · 2022: $14.58 · 2023: $25.78 · 2024: $42.19 · 2025: $27.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $180.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $149.94 | 2021 | |
| Gilead Sciences, INC. | $95.48 | 2023-2025 | Trodelvy |
| Amgen INC. | $72.75 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $65.00 | 2019 | |
| Horizon Therapeutics Plc | $59.28 | 2019-2020 | |
| Pfizer INC. | $48.16 | 2019-2021 | |
| Novo Nordisk INC | $29.03 | 2021 | |
| Aurinia Pharma U.S., INC. | $19.85 | 2021 | |
| Antares Pharma, INC. | $19.13 | 2021 | |
| Lilly USA, LLC | $18.86 | 2020 | |
| Mannkind Corporation | $18.15 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.43 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.58 | 2022 | |
| Genentech USA, INC. | $13.76 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.